PHARMACEUTICAL COMBINATION OF MILDRONATE AND ENALAPRIL

摘要

Pharmaceutical composition, containing 3-(2,2,2-trimethyldrazinium) propionate dihydrate or Mildronate and angiotensin converting enzyme (ACE) inhibitor, as combined preparation for treatment of cardiovascular diseases. It is proposed to use (S)-1-{N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl}-L-proline or Enalapril as ACE inhibitor. The advisable proportion of Mildronate and Enalapryl in the combination is within the range from 8:1 to 12:1.